Literature DB >> 23199962

Upgrading public health programs for human papillomavirus prevention and control is possible in low- and middle-income countries.

Marc Steben1, Jose Jeronimo, Scott Wittet, D Scott Lamontagne, Gina Ogilvie, Christina Jensen, Jennifer Smith, Silvia Franceschi.   

Abstract

Cancer is an important cause of premature death in low- and middle-income countries (LMIC). Two preventive tools are available that have the potential together to sharply decrease the impact of cervical cancer in LMIC. The combination of human papillomavirus (HPV) vaccination and cervical cancer screening within existing programs is possible. Although there is a great deal of concern about introducing and strengthening HPV prevention efforts in LMIC, recent projects have demonstrated feasibility. Thus, with appropriate prioritization and resources, HPV prevention can be introduced and scaled up. Comprehensive HPV prevention strategies, mainly those geared at preventing cervical cancer, should include both vaccination and screening. The integration of both screening and vaccination will save the most lives, and such strategies are endorsed by many international organizations. However, some vaccine and screening programs are financed almost entirely by special externally-based programs. These more closely resemble demonstration exercises than sustainable national programs. In order for successful demonstration projects to have a broad impact on prevention, sustainable national funding based on strong commitments is essential. There may be challenges to implementing HPV prevention programs, but none should be considered insurmountable. Many LMIC have successfully adopted an HPV prevention agenda despite prevailing pessimism. Failure to act on this issue can perpetuate inequity in sexually transmitted infection and cancer prevention. This article forms part of a special supplement entitled "Comprehensive Control of HPV Infections and Related Diseases" Vaccine Volume 30, Supplement 5, 2012.
Copyright © 2012. Published by Elsevier Ltd.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 23199962     DOI: 10.1016/j.vaccine.2012.06.031

Source DB:  PubMed          Journal:  Vaccine        ISSN: 0264-410X            Impact factor:   3.641


  11 in total

1.  Association between human papillomavirus and chlamydia trachomatis infection risk in women: a systematic review and meta-analysis.

Authors:  Giulia Naldini; Chiara Grisci; Manuela Chiavarini; Roberto Fabiani
Journal:  Int J Public Health       Date:  2019-06-08       Impact factor: 3.380

Review 2.  Economic Perspective of Cancer Care and Its Consequences for Vulnerable Groups.

Authors:  Joerg Haier; Juergen Schaefers
Journal:  Cancers (Basel)       Date:  2022-06-28       Impact factor: 6.575

Review 3.  HPV-FASTER: broadening the scope for prevention of HPV-related cancer.

Authors:  F Xavier Bosch; Claudia Robles; Mireia Díaz; Marc Arbyn; Iacopo Baussano; Christine Clavel; Guglielmo Ronco; Joakim Dillner; Matti Lehtinen; Karl-Ulrich Petry; Mario Poljak; Susanne K Kjaer; Chris J L M Meijer; Suzanne M Garland; Jorge Salmerón; Xavier Castellsagué; Laia Bruni; Silvia de Sanjosé; Jack Cuzick
Journal:  Nat Rev Clin Oncol       Date:  2015-09-01       Impact factor: 66.675

4.  Randomized controlled trial evaluating the utility of urine HPV DNA for cervical cancer screening in a Pacific Island population.

Authors:  Brenda Y Hernandez; Aileen C Tareg; Martina Reichhardt; Angelica Agapito; Xuemei Zhu; Angela Sy; Arnice Yuji; Jeffrey Killeen; Owen Chan; Lee E Buenconsejo-Lum
Journal:  J Glob Health Rep       Date:  2018-07-06

5.  Comprehensive control of human papillomavirus infections and related diseases.

Authors:  F Xavier Bosch; Thomas R Broker; David Forman; Anna-Barbara Moscicki; Maura L Gillison; John Doorbar; Peter L Stern; Margaret Stanley; Marc Arbyn; Mario Poljak; Jack Cuzick; Philip E Castle; John T Schiller; Lauri E Markowitz; William A Fisher; Karen Canfell; Lynette A Denny; Eduardo L Franco; Marc Steben; Mark A Kane; Mark Schiffman; Chris J L M Meijer; Rengaswamy Sankaranarayanan; Xavier Castellsagué; Jane J Kim; Maria Brotons; Laia Alemany; Ginesa Albero; Mireia Diaz; Silvia de Sanjosé
Journal:  Vaccine       Date:  2013-12-31       Impact factor: 3.641

6.  Implementation of an HPV vaccination program in Eldoret, Kenya: results from a qualitative assessment by key stakeholders.

Authors:  Heleen Vermandere; Violet Naanyu; Olivier Degomme; Kristien Michielsen
Journal:  BMC Public Health       Date:  2015-09-10       Impact factor: 3.295

Review 7.  Developing the Evidence Base to Inform Best Practice: A Scoping Study of Breast and Cervical Cancer Reviews in Low- and Middle-Income Countries.

Authors:  Margaret M Demment; Karen Peters; J Andrew Dykens; Ann Dozier; Haq Nawaz; Scott McIntosh; Jennifer S Smith; Angela Sy; Tracy Irwin; Thomas T Fogg; Mahmooda Khaliq; Rachel Blumenfeld; Mehran Massoudi; Timothy De Ver Dye
Journal:  PLoS One       Date:  2015-09-01       Impact factor: 3.240

8.  Experiences and lessons learned from 29 HPV vaccination programs implemented in 19 low and middle-income countries, 2009-2014.

Authors:  Joël Ladner; Marie-Hélène Besson; Etienne Audureau; Mariana Rodrigues; Joseph Saba
Journal:  BMC Health Serv Res       Date:  2016-10-13       Impact factor: 2.655

Review 9.  Sustaining Vaccine Confidence in the 21st Century.

Authors:  Karin Hardt; Ruprecht Schmidt-Ott; Steffen Glismann; Richard A Adegbola; François P Meurice
Journal:  Vaccines (Basel)       Date:  2013-06-24

Review 10.  Comprehensive control of human papillomavirus infections and related diseases.

Authors:  F Xavier Bosch; Thomas R Broker; David Forman; Anna-Barbara Moscicki; Maura L Gillison; John Doorbar; Peter L Stern; Margaret Stanley; Marc Arbyn; Mario Poljak; Jack Cuzick; Philip E Castle; John T Schiller; Lauri E Markowitz; William A Fisher; Karen Canfell; Lynette A Denny; Eduardo L Franco; Marc Steben; Mark A Kane; Mark Schiffman; Chris J L M Meijer; Rengaswamy Sankaranarayanan; Xavier Castellsagué; Jane J Kim; Maria Brotons; Laia Alemany; Ginesa Albero; Mireia Diaz; Silvia de Sanjosé
Journal:  Vaccine       Date:  2013-11-22       Impact factor: 3.641

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.